AUTHORITIES AND PARTIES Sample Clauses

AUTHORITIES AND PARTIES. 14 1. The United States Environmental Protection Agency (“EPA” or “Complainant”), 15 Region IX and Respondents Fileminders of Hawaii, LLC (“Fileminders”) and Hawaii MMGD 16 LLC (“MMGD”) (collectively the “Parties”) agree to settle this matter and consent to the entry 17 of this Consent Agreement and [Proposed] Final Order (“CA/FO”), which commences this 18 proceeding in accordance with 40 C.F.R. §§ 22.13(b), 22.18(b)(2) and 22.45(b). Pursuant to 40 19 C.F.R. § 22.18(b)(3), this proceeding will conclude upon the issuance of a Final Order by the 20 Regional Judicial Officer. 21 2. This is a civil administrative action instituted by EPA Region IX against Respondents pursuant to Section 1423(c) of the Safe Drinking Water Act (“SDWA”), 42 U.S.C. § 300h-2(c), for violations of the SDWA and the Underground Injection Control (“UIC”) 24 requirements set forth at 40 C.F.R. Part 144.
Sample 1Sample 2
AutoNDA by SimpleDocs
AUTHORITIES AND PARTIES. 1. The United States Environmental Protection Agency (“EPA” or “Complainant”), Region IX and Respondent Group Investments, LLC. (“Group Investments”) (collectively the “Parties”) agree to settle this matter and consent to the entry of this Consent Agreement and Final Order (“CA/FO”), which commences this proceeding in accordance with 40 C.F.R. §§ 22.13(b), 22.18(b)(2) and 22.45(b). Pursuant to 40 C.F.R. § 22.18(b)(3), this proceeding will conclude upon the issuance of a final order by the Regional Judicial Officer. 2. This is a civil administrative action instituted by EPA Region IX against Respondent pursuant to Section 1423(c) of the Safe Drinking Water Act (“SDWA”), 42 U.S.C. § 300h-2(c), for violations of the SDWA and the Underground Injection Control (“UIC”) requirements set forth at 40 C.F.R. Part 144. 3. Complainant is the Director of the Enforcement and Compliance Assurance Division, EPA Region IX. The Administrator of EPA delegated to the Regional Administrator of EPA Region IX the authority to bring and settle this action under SDWA. In turn, the Regional Administrator of EPA Region IX further delegated the authority to bring and sign a consent agreement settling this action under SDWA to the Director of the Enforcement and Compliance Assurance Division. 4. Respondent, Group Investments, is a Hawaii company with its principal place of business located at 000 Xxxxxxx Xxxxxx, Xxxxxxxx, Xxxxxx, 00000-0000.
Sample 1
AUTHORITIES AND PARTIES. 12 1. The United States Environmental Protection Agency (“EPA”), Region IX and the 13 State of Hawaiʻi, Department of Human Services (“Respondent”) (collectively the “Parties”) 14 agree to settle this matter and consent to the filing of this Consent Agreement and Final Order
Sample 1
AUTHORITIES AND PARTIES. National Aeronautics and Space Administration (hereinafter referred to as “NASA”), located at 000 X Xxxxxx XX, Xxxxxxxxxx XX 00000, and the Department of Energy (hereinafter referred to as “DOE”) located at 0000 Xxxxxxxxxxxx Xxxxxx XX, Xxxxxxxxxx, XX 00000 enter into this Memorandum of Agreement (MOA) in accordance with the National Aeronautics and Space Act (51 U.S.C. § 20113(e)), the Atomic Energy Act of 1954, as amended (42 U.S.C. § 2051), Section 107 of the Energy Reorganization Act of 1974 (42 U.S.C. § 5817), Section 646 of the Department of Energy Organization Act (42 U.S.C. 7256), and Section 976 of the Energy Policy Act of 2005 (42 U.S.C. § 16316),. NASA and DOE may be individually referred to as a “Party” and collectively referred to as the “Parties.” This agreement in no way restricts either of the Parties from participating in any activity with other public or private agencies, organizations, or individuals.
Sample 1

Related to AUTHORITIES AND PARTIES

  • Notice to Taxing Authorities and Insurance Companies The Seller shall transmit to the applicable taxing authorities and insurance companies (including primary mortgage insurance policy insurers, if applicable) and/or agents, notification of the transfer of the servicing to the Purchaser, or its designee, and instructions to deliver all notices, tax bills and insurance statements, as the case may be, to the Purchaser from and after the Transfer Date. The Seller shall provide the Purchaser with copies of all such notices within five (5) Business Days following the Transfer Date;

  • AUTHORITIES Intergovernmental Personnel Mobility Act, 5 U.S.C. §§ 3371-3376 • Executive Order 13171, Hispanic Employment in the Federal Government • Executive Order 13518, Employment of Veterans in the Federal Government • Executive Order 13548, Increasing Federal Employment of Individuals with Disabilities • Executive Order 13555, White House Initiative on Educational Excellence for Hispanics • Executive Order 13562, Recruiting and Hiring Students and Recent Graduates • Executive Order 13583, Establishing a Coordinated Government-wide Initiative to Promote Diversity and Inclusion in the Federal Workforce • Executive Order 13592, Improving American Indian and Alaska Native Educational Opportunities and Strengthening Tribal Colleges and Universities • Executive Order 13621, White House Initiative on Educational Excellence for African Americans • Executive Order 13779, White House Initiative to Promote Excellence and Innovation at Historically Black Colleges and Universities (HBCU) • Executive Order 13872, Economic Empowerment of Asian Americans, and Pacific Islanders • Any other superseding and subsequent authorities

  • Studies and Reports All copies in the Seller’s possession of studies and/or reports which have previously been performed in connection with or for the Property, including without limitation, environmental reports, soils studies, seismic studies, physical inspection reports, site plans and surveys, and identification of such studies of which the Seller is aware but that are not in their possession;

  • Certificates, Authorities and Permits The Company and each Subsidiary possess adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company or such Subsidiary, could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.

  • Governmental Authorities From the date of this Agreement and until the End Date, the Company shall duly observe and conform in all material respects to all valid requirements of governmental authorities relating to the conduct of its business or to its properties or assets.

  • Regulatory Matters and Approvals Each of the Parties will give any notices to, make any filings with, and use its reasonable best efforts to obtain any necessary authorizations, consents, and approvals of governments and governmental agencies in connection with the transactions contemplated by this Agreement. Without limiting the generality of the foregoing:

  • Consents and Approvals of Governmental Authorities No consent, approval, or authorization of, or declaration, filing, or registration with, any governmental or regulatory authority is required to be made or obtained by the Seller in connection with the execution, delivery, and performance of this Agreement or any of the other Acquisition Documents by the Seller.

  • Regulatory Consents and Approvals All consents, approvals and actions of, filings with and notices to any Governmental or Regulatory Authority necessary to permit Purchaser and Seller to perform their obligations under this Agreement and the Operative Agreements and to consummate the transactions contemplated hereby and thereby (a) shall have been duly obtained, made or given, (b) shall be in form and substance reasonably satisfactory to Purchaser, (c) shall not be subject to the satisfaction of any condition that has not been satisfied or waived and (d) shall be in full force and effect, and all terminations or expirations of waiting periods imposed by any Governmental or Regulatory Authority necessary for the consummation of the transactions contemplated by this Agreement and the Operative Agreements shall have occurred.

  • AUTHORITY AND PARTIES In accordance with the National Aeronautics and Space Act (51 U.S.C. § 20113), this Agreement is entered into by the National Aeronautics and Space Administration, located at 000 X Xxxxxx XX, Xxxxxxxxxx, XX 00000 (hereinafter referred to as "NASA") and Xxxxxx Space Systems, Inc., located at 0000 Xxxxxxxx Xx., Xxxxxx, XX 00000 (hereinafter referred to as "Partner" or "Xxxxxx"). NASA and Partner may be individually referred to as a "Party" and collectively referred to as the "Parties."

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package or the Prospectus, each of the Company and its subsidiaries: (a) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (“Applicable Laws”); (b) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the Company (“Governmental Authority”) alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (c) possesses all Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (d) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product, operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (e) has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is considering such action; and (f) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission). The studies, tests and preclinical and clinical trials material to the Company and its subsidiaries taken as a whole, and conducted by or on behalf of the Company and each of its subsidiaries, were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package or the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus when viewed in the context in which such results are described and the clinical state of development; and neither the Company nor any of its subsidiaries has received any notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are material to the Company and its subsidiaries taken as a whole.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!